Shen Yunjie, Wu Bin, Wang Xiaohui, Zhu Jun
Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China.
Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China.
J Comp Eff Res. 2018 May;7(5):443-452. doi: 10.2217/cer-2017-0069. Epub 2018 May 18.
Non-small-cell lung cancer (NSCLC) is a leading global health threat that impairs patient health outcomes. Health state utilities are fundamental values in economic evaluation and significantly vary across countries. Given the scarce data on the Chinese population, the current study measured utility values in the Chinese patients with NSCLC.
This study was conducted as a cross-sectional survey of patients with advanced NSCLC at the Shanghai Chest Hospital. Utility values were assessed using the EuroQol five-dimension (EQ-5D) instrument and scored based on the Chinese-specific value algorithm. Predictors of utility values were examined using a subgroup analysis and a multiple regression model.
The mean EQ-5D utility value of recruited patients was 0.814. The regression analysis revealed that tumor stage, treatment regimen and line of therapy were the potential predictors of utility values.
This study provides the Chinese-specific health utility data for advanced NSCLC using the EQ-5D.
非小细胞肺癌（NSCLC）是全球主要的健康威胁，会损害患者的健康结局。健康状态效用值是经济评估中的基本价值，且在不同国家存在显著差异。鉴于针对中国人群的数据稀缺，本研究测量了中国非小细胞肺癌患者的效用值。
本研究以上海胸科医院的晚期非小细胞肺癌患者为对象进行了横断面调查。使用欧洲五维健康量表（EQ-5D）工具评估效用值，并根据中国特定的价值算法进行评分。通过亚组分析和多元回归模型检查效用值的预测因素。
招募患者的平均EQ-5D效用值为0.814。回归分析显示，肿瘤分期、治疗方案和治疗线数是效用值的潜在预测因素。
本研究使用EQ-5D提供了中国晚期非小细胞肺癌患者特定的健康效用数据。
